The paediatric neuropathic bladder by Lazarus, John
CONTINUING MEDICAL EDUCATION
    March 2014, Vol. 104, No. 3
A neurogenic bladder can be defined as a dysfunctinal urinary 
bladder caused by disease of the central nervous system or peripheral 
nerves involved in the control of micturition (urination). In 
pathophysiological terms, a neurogenic bladder is caused by a 
spinal reflex arc that occurs when the bladder becomes autonomous 
from higher centres.[1] Paediatric neurogenic bladder dysfunction is 
most commonly caused by a congenital neural tube defect (NTD), 
such as myelomeningocele (MMC) or another form of tethered 
spinal cord. Alternatively, it can be the result of traumatic spinal 
cord injury, transverse myelitis or anorectal malformation. The 
standard conservative management of paediatric neurogenic bladder 
comprises clean intermittent catheterisation and oral anticholinergic 
medication. This article covers the available literature on the ideal 
assessment of and contemporary treatment options for this vulnerable 
group of children.
Physiology of micturition
The normally functioning lower urinary tract brings about low-
pressure bladder storage and continence, followed by periodic, 
complete voluntary voiding. Hence, the micturition reflex is best 
divided into two discrete phases, i.e. bladder filling/urine storage and 
bladder emptying/voiding.
Micturition and storage are functions of the parasympathetic 
and sympathetic nervous systems, respectively. Both are therefore 
functions of the autonomic nervous system, while the somatic 
nervous system controls the external urinary sphincter, allowing 
continence.
The normal micturition reflex involves switching from inhibition of 
the voiding reflex and activation of storage reflexes to inhibition of the 
storage reflexes and activation of the voiding reflex – and back again.
Assessment
Many children with a neurogenic bladder have urinary incontinence 
and potential progressive renal damage because of high bladder 
storage pressures, secondary vesico-ureteric reflux and recurrent 
urinary tract infections (UTIs). Children at risk of renal damage 
should undergo a thorough medical history (including a bladder 
diary), neurological examination, urinalysis and culture to identify 
infection. Serial renal ultrasonography allows the renal tract to be 
monitored and cystography can be used to reveal the configuration 
of the bladder and detect vesico-ureteric reflux that occurs as a 
secondary phenomenon in the neurogenic bladder. Nuclear imaging, 
glomerular filtration rate estimation and, at a later stage, serum 
creatinine level, can also be used to assess kidney function.
Urodynamic assessment is essential for the diagnosis and prognosis 
of paediatric neurogenic bladder. Urodynamic studies (UDSs) are 
functional studies of the lower urinary tract; they evaluate storage and 
emptying functions of the bladder. UDSs can be simple and non-invasive 
(bladder diary and flow rate) or invasive (cystometrogram and video-
urodynamics). A cystometrogram measures the relationship between 
bladder filling and pressure. Parameters used to characterise the bladder 
are capacity, compliance, detrusor activity and sphincter activity (Fig.1). 
On the other hand, invasive UDSs are indicated to evaluate and 
characterise the neuropathic bladder. UDSs should be used early in 
the management and repeated to avoid upper tract deterioration. 
Paediatric patients with MMC should first undergo UDSs in the 
neonatal period, but this service is rarely available in South Africa 
(Fig. 2). However, as it is a test essential to the quality care of these 
children and adults, UDSs should be fostered nationally.
Risk factors signalling a poor prognosis include: 
• reduced bladder capacity for age
• poor compliance
• elevated detrusor leak point pressure (>40 cmH2O) 
• features of functional bladder outlet obstruction on 
electromyography, such as detrusor sphincter dyssynergia.[2]
Fig. 3 demonstrates the cystometrogram of a patient with a 
neuropathic bladder secondary to MMC. It shows, from top to 
bottom, the vesical, abdominal, and detrusor (computer-calculated) 
traces. Compared with a normal  cystometrogram, there is a steep 
rise in the pressure v. time trace with bladder filling, representing 
a typical poorly compliant bladder, where the capacity is reduced 
and the detrusor leak point pressure is elevated above the danger 
threshold of 40 cmH2O. Above this value, urinary flow from the 
kidneys is impaired. Additionally, there are small waves of detrusor 
instability throughout the study, bladder sensation is reduced and 
incontinence occurs.
The UDS bladder dysfunction pattern can be dynamic, and 
warrants close monitoring and life-long follow-up. This diagnostic 
assessment allows each child to be categorised into one of four 
subtypes of neuropathic bladder dysfunction based on sphincter and 
detrusor muscle activity (Table 1).[3] Although these categories may 
ARTICLE
The paediatric neuropathic bladder
J Lazarus, MB ChB, MMed Urology, MA, FCUrol (SA)
Division of Urology, Red Cross War Memorial Children’s Hospital, University of Cape Town, South Africa 
Corresponding author: J Lazarus (j.lazarus@uct.ac.za)
Paediatric neuropathic bladder dysfunction can cause irreversible renal damage and urinary incontinence. Aetiologically, this condition is 
usually caused by a congenital neural tube defect. The majority of affected children can be successfully managed with the standard medical 
treatment of clean intermittent catheterisation and anticholinergic medication (typically oxybutynin). A small subset of patients who receive 
oral oxybutynin experience severe side-effects or insufficient suppression of detrusor overactivity. This group may require alternative 
medical or surgical management.
S Afr Med J 2014;104(3):220. DOI:10.7196/SAMJ.8046
CONTINUING MEDICAL EDUCATION
    March 2014, Vol. 104, No. 3
overlap, they assist in patient management. Anticholinergic drugs 
might at best be expected to treat the neurogenic detrusor overactivity 
associated with types B and D by improving functional capacity and 
reducing filling pressures. Types A and C usually require clean 
intermittent catheterisation alone, with marginal benefit expected 
from anticholinergics.
Management
The primary goals of paediatric neurogenic bladder management 
are to normalise vesical pressure and to achieve social continence. 
Additionally, 58% of children with untreated MMC exhibit progressive 
renal deterioration by 3 years of age;[4] therefore the early treatment of 
these children can also improve renal function.[5] 
Pharmacotherapy
During normal bladder function, acetylcholine released from 
parasympathetic nerves activates muscarinic receptors in this organ, 
causing detrusor contraction and resultant micturition. In patients 
with a neuropathic bladder, disordered innervation commonly 
results in dyssynergia between the detrusor and external sphincters, 
which adversely affects bladder function. 
There are five subtypes of muscarinic receptors expressed in the 
bladder. Of these, M2 receptors are the most abundant, although 
M3 receptors are more functionally active.[6] Oral anticholinergics, 
such as oxybutynin, block these receptors, causing relaxation of 
the bladder’s smooth muscle, and are well established as the first-
line pharmacotherapeutic agents for neurogenic bladder in adults 
and children. The majority of children with neurogenic bladder 
(70 - 90%) are effectively managed with oral anticholinergics and 
clean intermittent catheterisation, avoiding the need for surgical 
intervention, e.g. augmentation cystoplasty or bladder outlet surgery.[7] 
Of the anticholinergic agents available, few have regulatory approval 
for use in children. Oxybutynin chloride is FDA approved. It is 
widely used, and long-term treatment supports its safety in children, 
including newborns.[3] The limitations of oral anticholinergic use 
are the associated side-effects and that a subset of children fail 
to adequately respond to this therapy. Inadequate responses are 
characterised by ongoing urinary incontinence, which can reduce 
quality of life and cause progressive upper-tract dilatation and loss of 
renal cortical mass. Side-effects of anticholinergic agents include dry 
mouth, blurred vision, constipation, facial flushing and dizziness. Of 
significant concern are the suggested cognitive side-effects, particularly 
as these children represent a neurologically vulnerable cohort.[8]
Table 1. The four subtypes of paediatric neurogenic bladder
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Type Sphincter Detrusor
A Overactive Underactive
B Overactive Overactive
C Underactive Underactive
D Underactive Overactive
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Fig. 1. Typical urodynamic study set-up: dual lumen catheter to allow 
simultaneous infusion and pressure measurement with a separate rectal 
catheter as a control for intra-abdominal pressure, thus allowing computer-
derived true detrusor pressure. 
Fig. 2. Dedicated paediatric urodynamic and sonar suite at Red Cross War 
Memorial Children’s Hospital.
Fig. 3. A cystometrogram showing the typical steep trace of a poorly compliant 
bladder with reduced capacity and elevated detrusor leak point pressure.
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For children who are not controlled by anticholinergic therapy 
and clean intermittent catheterisation, other options need to be 
explored, as discussed below. These patients may have persistent 
hydronephrosis, new renal scarring, vesico-ureteric reflux, persistent 
incontinence or UTIs. 
While immediate-release oxybutynin is widely used in children 
with neuropathic bladders, innovative drug delivery systems hold the 
potential to improve clinical outcomes. Extended-release oxybutynin 
and tolteridine are also available. Transcutaneous extended-release 
oxybutynin has been shown in a large trial to be well tolerated, with 
few undesired anticholinergic side-effects, apart from some skin 
reactions. Furthermore, new-generation anticholinergic agents, such 
as darifenacin and solifenacin, are selective for the M3 receptor and 
thus offer the potential of reduced side-effects. However, few of these 
newer drugs have regulatory approval for paediatric use.
Brendler et al.[9] were the first to document the intravesical delivery 
of oxybutynin in adult patients with persistent urge incontinence. 
The authors claimed that the increased efficacy and reduced side-
effect profile observed with intravesical administration were due to 
lower plasma drug levels. Counter-intuitively, the serum levels of 
oxybutynin after intravesical administration are as high as when taken 
orally.[1] However, since first-pass liver metabolism is circumvented 
with this approach, a reduced side-effect profile is observed. Side-
effects are predominantly thought to be mediated by the metabolite 
N-desethyl oxybutynin.[10]
Botulinum toxin type A injection into the detrusor muscle was first 
reported in 2000 and has since been widely studied. The neurotoxin 
binds to the presynaptic nerve endings of cholinergic neurons, 
resulting in a marked reduction in bladder contractions. The efficacy 
of botulinum toxin type A injections in children with neurogenic 
bladders due to spina bifida was described in 2002; 85 - 300 U of 
botulinum toxin type A was injected into the detrusor muscle, 
causing an increase in average maximum bladder capacity and 
detrusor compliance, and a decrease in the mean maximal detrusor 
pressure. Continence was restored in all 17 children investigated.[1] A 
further study demonstrated a reduced requirement for oral medication 
and improved quality of life for children treated with botulinum toxin 
type A.[11] Urodynamic efficacy lasts for about 6 months, after which 
repeated injections are necessary.
Clean intermittent catheterisation
Clean intermittent catheterisation is a cornerstone of lifelong 
management. It is a safe and an effective method of completely 
emptying the bladder, improving or eliminating urinary incontinence, 
reducing UTIs and protecting (along with anticholinergics) kidney 
function. 
Clean intermittent catheterisation should be done 3-hourly. The 
Credé manoeuvre (manual suprapubic pressure to expel urine) is 
discouraged.
Surgery
Surgical options for failure of conservative treatment typically use a 
segment of bowel to enlarge the bladder (augmentation cystoplasty), 
which increases capacity and reduces pressure. 
For children with an underactive sphincter (Table 1) who 
are incontinent with a good-capacity and low-pressure bladder, 
bladder outlet surgery, e.g. an artificial urinary sphincter, may  be 
contemplated.
Conclusion
Children with neuropathic bladders resulting from MMC require 
life-long surveillance and treatment, ideally in a multidisciplinary 
environment. South African medical services need to rise to this 
challenge and render appropriate care to this vulnerable group of 
patients. 
Some of the information in this article is drawn from a previous 
publication by the author.[12] 
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